Plain-English translation of NCT05819541 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied whether montelukast—a medication that reduces inflammation in the airways—could help children with severe asthma attacks recover more quickly when given at higher doses than normally used. Researchers tested different dose levels of the medication to find the right amount that would work effectively during emergency asthma treatment. The study compared children who received this treatment alongside standard emergency care to children who received standard care alone.
Doctors know that high-dose intravenous (IV) forms of this medication help adults with severe asthma attacks, but IV montelukast is not available for use. This trial aimed to find an oral dose that could achieve similar benefits in children without needing an IV, potentially helping more children recover faster during asthma emergencies.
Participants were randomly assigned to receive either the higher-dose study medication or a placebo (inactive powder), both added to the standard emergency asthma treatment they received at the hospital. Children received their assigned treatment during their emergency hospital visit and then completed follow-up questionnaires about their recovery and any side effects 2–3 weeks later by phone or mail.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States